On December 12th 2014, the State Intellectual Property Office and the World Intellectual Property Organization held the ceremony of the 16th WIPO-SIPO Award for Chinese Outstanding Patented Invention & Industrial Design in the auditorium on the third floor of Building No. 1 of the State Intellectual Property Office. The company’s patented program, “Icotinib Hydrochloride as well as its preparation method, crystal form, pharmaceutical compositions and purposes” (Patent No.: ZL20098-0100666.1), won the gold medal of the award.
This is the second time that the company won the gold medal of the WIPO-SIPO Award for WIPO-SIPO Award for Chinese Outstanding Patented Invention & Industrial Design after its patented program, “New Type Fused Quinazoline Derivative as Tyrosine Kinase Inhibitor”(Patent No.: 03108814.7), claimed the same honor at the 14th ceremony in 2012. Icotinib Hydrochloride Tablets (Product Name: Conmana) successfully broke the monopoly of the foreign pharmaceutical enterprisesin this field, and filled China’s gap in independent development of targeted drugs. Since it went onto the market in August 2011, Conmana has been adopted and used by nearly 1,000 oncologists and nearly 40,000patients.